ORAPRED ODT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORAPRED ODT (ORAPRED ODT).
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and subsequent anti-inflammatory and immunosuppressive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production.
| Metabolism | Primarily hepatic via CYP3A4; prednisolone is the active metabolite of prednisone. |
| Excretion | Primarily renal (80-90% as inactive glucuronide and sulfate conjugates; less than 10% as unchanged drug). Biliary/fecal excretion accounts for about 5%. |
| Half-life | Terminal elimination half-life: 2-3 hours (after IV/IM/oral). Clinically, anti-inflammatory effects persist beyond plasma half-life due to glucocorticoid receptor-mediated gene transcription effects. |
| Protein binding | 90-95% primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Vd: 0.5-0.8 L/kg (approx 35-56 L in 70 kg adult). Indicates distribution into total body water, readily penetrates tissues including central nervous system. |
| Bioavailability | Oral: 70-90% (well absorbed). Intravenous: 100%. Rectal (enema): variable, about 30-50% of oral. |
| Onset of Action | Oral: 1-2 hours (peak effect at 1-2 hours). Intravenous: within 2-30 minutes. Intra-articular: 1-2 days. |
| Duration of Action | Oral: biological duration of action is 1-2 days (due to receptor-mediated effects). Clinical duration of anti-inflammatory effect: 2-3 days after single dose. Intra-articular: 2-3 weeks. |
10-60 mg orally once daily or divided twice daily; maximum 60 mg/day.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | No adjustment necessary; drug is metabolized in liver. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | 0.5-2 mg/kg orally per day in divided doses every 12 hours; maximum 60 mg/day. |
| Geriatric use | Start at lower end of dosing range; monitor for fluid retention, hyperglycemia, and osteoporosis. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORAPRED ODT (ORAPRED ODT).
| Breastfeeding | Prednisolone enters breast milk; M/P ratio approximately 0.13. Nursing while taking ≤40 mg/day is generally considered acceptable. Monitor infant for adrenal suppression. |
| Teratogenic Risk | Orapred ODT (prednisolone sodium phosphate) is a corticosteroid. First trimester: Increased risk of cleft palate (odds ratio 3.4). Second trimester: Possible intrauterine growth restriction. Third trimester: Risk of adrenal suppression in neonate. Use only if benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles, and if exposed, to seek medical advice.
| Serious Effects |
["Systemic fungal infections","Hypersensitivity to prednisolone or any component","Administration of live or live attenuated vaccines (relative)"]
| Precautions | ["Increased risk of infections due to immunosuppression","Adrenal suppression and insufficiency upon withdrawal","Masking of signs of infection","Increased risk of GI perforation in certain conditions","Osteoporosis with prolonged use","Growth suppression in children"] |
Loading safety data…
| Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal ultrasound for growth restriction. Assess neonatal adrenal function if used in late pregnancy. |
| Fertility Effects | No known adverse effect on fertility in humans. In animal studies, high doses caused impaired spermatogenesis; relevance unknown. |